Biogen (BIIB)
| Company | Ticker | Sector | Industry | Quality | PAR |
|---|---|---|---|---|
| Biogen | BIIB | Healthcare | Drug Manufacturers - General | 45 | -2.8% |
| Current Price ( 5/26 4:00PM EDT) | $298.66 | |||
| CAPS Rating (Rate this stock on CAPS) |  |
|||
| Expected Income Statement | ||||
| Current Sales | 10,104.6 | |||
| Sales Growth Forecast | -0.1% | |||
| Net Profit Margin | 16.0% | |||
| Projected Shares Outstanding | 129.96 | |||
| EPS - Five year Forecast | $12.36 | |||
| Average P/E Ratio | 21.0 | |||
| Projected Average Price | $259.55 | |||
| Price Appreciation (Annualized) | -2.8% | |||
| Annual Dividend Yield | 0.0% | |||
| Projected Annual Return | -2.8% | |||
| Quality | ||||
| Financial Strength | 89 | 22.2 | ||
| EPS Stability | 45 | 11.2 | ||
| Industry Sales Growth Rate | 4.0% | -0.4 | ||
| Industry Net Profit Margin | 19.3% | 10.4 | ||
| Calculated Quality Rating | 43.3 | |||
| Fool CAPS | ||||
Total Players
955
Outperforms
76
Underperforms
All-Stars (215)
202
Outperforms (94%)
13
Underperforms
|
||||
| Fundamental Data Updated: 03/31/2023 | ||||